Showing results (271-280 of 1,186) with videos related to
Sort By:
Pageof 119
Pharmaceutical Statistics|May 1, 2026
Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case StudyAndrea Callegaro, Francesca Solmi, Silvia Noirjean, et al.Pharmaceutical Statistics|August 6, 2023
A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncologyKentaro Takeda, Jing Zhu, Ran Li, et al.Pharmaceutical Statistics|July 7, 2023
Determining the minimum duration of treatment in tuberculosis: An order restricted non-inferiority trial designAlessandra Serra, Pavel Mozgunov, Geraint Davies, et al.Pharmaceutical Statistics|July 10, 2023
Two-sample inference procedures under nonproportional hazardsYi-Cheng Tai, Weijing Wang, Martin T WellsPharmaceutical Statistics|May 10, 2019
Choosing between the BP and BN sequential strategiesDonna K McClish, Amber R Wilk, Christine M SchubertPharmaceutical Statistics|June 26, 2026
Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error ControlQuynh Nguyen, Martin Posch, Benjamin Hofner, et al.Pharmaceutical Statistics|June 20, 2026
Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary DiseasesParthkumar Rabari, Purbasha Biswas, Jing X Kersey, et al.Pharmaceutical Statistics|August 27, 2019
A GEE approach to estimating accuracy and its confidence intervals for correlated dataYaeji LimPharmaceutical Statistics|September 18, 2014
Fitting Emax models to clinical trial dose-response data when the high dose asymptote is ill definedP Brain, S Kirby, R LarionovPharmaceutical Statistics|August 12, 2016
Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion familyWei Jiang, Jonathan D Mahnken, Jianghua He, et al.Pageof 119